Comparison of 18FD3FSP(18FP16-129) and 18F AV45 in Alzheimers Disease
Conclusions: In this small sample of 6 AD subjects, there were no substantial differences between [18F]D3FSP vs. [18F]AV45 but, 50% of the subjects did have slightly higher global cortical SUVR with [18F]D3FSP vs. [18F]AV45. Although all had a clinical diagnosis of AD, some of the subjects had only moderate quantitative uptake using the [18F]AV45 criteria. Visual inspection suggests [18F]D3FSP vs. [18F]AV45 may have some subtle differences in clinical readings and there may be quantitative differences in some individual cases but a larger population is needed with more severe patients before concluding the potential improved diagnostic value of [18F]D3FSP. Support by Five Eleven Pharma Inc.
Nuclear medicine and molecular imaging advocates went to Capitol Hill in Washington,...Read more on AuntMinnie.comRelated Reading: Video from SNMMI 2019: Dr. Barry Siegel on PET reimbursement IMV: PET/CT drives PET scan volume to new heights IDEAS study confirms amyloid PET's value for Alzheimer's Both sides weigh in on plan to loosen radiopharma rules How Medicare fee schedule changes will affect radiology
Publication date: Available online 15 July 2019Source: NeuroImageAuthor(s): Alex M. Pagnozzi, Jurgen Fripp, Stephen E. RoseAbstractThe deep grey matter (DGM) nuclei of the brain play a crucial role in learning, behaviour, cognition, movement and memory. Although automated segmentation strategies can provide insight into the impact of multiple neurological conditions affecting these structures, such as Multiple Sclerosis (MS), Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD) and Cerebral Palsy (CP), there are a number of technical challenges limiting an accurate automated segmentation of the DGM...
This multicenter longitudinal cohort study of 741 participants uses in vivo β-amyloid cerebrospinal fluid and positron emission tomography findings to track progression of Alzheimer disease across 6 years of follow-up.
CONCLUSIONS: Amyloid-PET positivity is associated with lower MoCA scores. Clinical utility of amyloid-PET scan is likely to be suboptimal at the MoCA score cutoff for minimal cognitive impairment. PMID: 31305321 [PubMed - as supplied by publisher]
LOS ANGELES (AP) — Scientists are closing in on a long-sought goal — a blood test to screen people for possible signs of Alzheimer’s disease and other forms of dementia. On Monday at the Alzheimer’s Association International Conference, half a dozen research groups gave new results on various experimental tests, including one that seems 88% accurate at indicating Alzheimer’s risk. Doctors are hoping for something to use during routine exams, where most dementia symptoms are evaluated, to gauge who needs more extensive testing. Current tools such as brain scans and spinal fluid tests are too ex...
ConclusionIn patients with higher levels of education, tau pathology is less paralleled by regional and remote neuronal dysfunction. The data suggest that early life-time factors such as level of education support resilience mechanisms, which ameliorate AD-related effects later in life.
ConclusionsSNAP subjects show milder impairment of brain [18F] FDG uptake as compared to AD. The partial overlap of the metabolic pattern between SNAP and AD limits the use of [18F] FDG PET/CT in effectively discriminating these clinical entities.
CONCLUSIONS: Our results suggest that the mechanism underlying low CSF Aβ levels differs between amyloid PET(-) iNPH and amyloid PET(+) AD subjects. The lower levels of all CSF biomarkers in iNPH patients might be due to reduced clearances from extracellular fluid and decreased brain metabolism of the periventricular zone in iNPH resulting from glymphatic dysfunction. PMID: 31286708 [PubMed]
CONCLUSIONS: Limited data of in vivo CTE biomarkers with postmortem confirmation are available. While some data exist, they are limited by selection bias. It is unlikely that a single test will be sufficient to properly diagnosis and distinguish CTE from other neurodegenerative diseases such as Alzheimer disease or Frontotemporal Dementia. However, with a combination of fluid biomarkers, neuroimaging, and genetic testing, early detection may become possible. PMID: 31287716 [PubMed - as supplied by publisher]
Abstract Adenosine receptors (ARs) are a class of purinergic G-protein-coupled receptors (GPCRs). Extracellular adenosine is a pivotal regulation molecule that adjusts physiological function through the interaction with four ARs: A1R, A2AR, A2BR, and A3R. Alterations of ARs function and expression have been studied in neurological diseases (epilepsy, Alzheimer's disease, and Parkinson's disease), cardiovascular diseases, cancer, and inflammation and autoimmune diseases. A series of positron emission tomography (PET) probes for imaging ARs have been developed. The PET imaging probes have provided valuable informati...